CLDN18 and neoplasm: CLDN18.2-specific second-generation CAR-T cells coexpressing IL-7 and CCL21 were tested in vitro and in vivo in three tumor models (breast, pancreatic and hepatocellular carcinoma) and revealed superior therapeutic effects to either conventional CAR-T cells or 7 × 19 CAR-T cells, without preconditioned lymphodepletion.